4.6 Article

Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies

Journal

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2012.04.028

Keywords

adverse outcome; maternal antidepressant; preterm birth

Funding

  1. Bristol-Myers Squibb
  2. Eli Lilly and Company
  3. Euthymics Bioscience
  4. Forest Pharmaceuticals
  5. Janssen Pharmaceutica
  6. Novartis Pharmaceuticals
  7. Otsuka Pharmaceuticals
  8. Pamlab
  9. Pfizer
  10. Repligen
  11. St. Jude Medical
  12. Vanderbilt CTSA from the National Institutes of Health [UL1 RR024975-01]
  13. [R03 MH 088902]
  14. [K12 scholar HD 043483]
  15. [1RC4MH092755-01]
  16. [K24 AI 77930]

Ask authors/readers for more resources

OBJECTIVE: The purpose of this study was to describe antidepressant medication use patterns during pregnancy and pregnancy outcomes. STUDY DESIGN: We evaluated a cohort of 228,876 singleton pregnancies that were covered by Tennessee Medicaid, 1995-2007. RESULTS: Of 23,280 pregnant women with antidepressant prescriptions before pregnancy, 75% of them filled none in the second or third trimesters of pregnancy, and 10.7% of them used antidepressants throughout pregnancy. Filling 1, 2, and >= 3 antidepressant prescriptions during the second trimester was associated with shortened gestational age by 1.7 (95% confidence interval [CI], 1.2-2.3), 3.7 (95% CI, 2.8-4.6), and 4.9 (95% CI, 3.9-5.8) days, when controlled for measured confounders. Third-trimester selective serotonin reuptake inhibitor use was associated with infant convulsions; adjusted odds ratios were 1.4 (95% CI, 0.7-2.8); 2.8 (95% CI, 1.9-5.5); and 4.9 (95% CI, 2.6-9.5) for filling 1, 2, and >= 3 prescriptions, respectively. CONCLUSION: Most women discontinue antidepressant medications before or during the first trimester of pregnancy. Second-trimester antidepressant use is associated with preterm birth, and third-trimester selective serotonin reuptake inhibitor use is associated with infant convulsions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available